Daré Bioscience Regains Compliance With Nasdaq Minimum Bid Price Rule

7/19/24 8:02:09 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DARE alert in real time by email

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company's common stock being $1.00 per share or greater for 10 consecutive trading sessions and that the matter is closed.

Get the next $DARE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DARE

Date	Price Target	Rating	Analyst
6/30/2021	$9.00 → $11.00	Buy	Roth Capital

More analyst ratings

$DARE
Press Releases

Fastest customizable press release news feed in the world

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the development timeline Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder - continued operational progress toward a planned Phase 3 study, including constructive discussions with FDA; Phase 3 design, development, and collaboration strategy updates
11/14/24 4:01:00 PM ET
$DARE
Biotechnology: Pharmaceutical Preparations
Health Care
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
- Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. - Grant will also provide funding to allow Daré to expand the number of clinical sites in the ongoing Ovaprene® pivotal study to accelerate the development timeline. SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced it entered into a grant agreement with the Bill & Melinda Gates Foundation for a grant of up to approximately $10.7 million to fund activities related to the identification and development of a novel non-hormon
11/13/24 8:00:00 AM ET
$DARE
Biotechnology: Pharmaceutical Preparations
Health Care
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Thursday, November 14, 2024, and prior to the conference call and webcast. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 6400145. The live webcast can be accessed under
11/7/24 8:00:00 AM ET
$DARE
Biotechnology: Pharmaceutical Preparations
Health Care

$DARE
Financials

Live finance-specific insights

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the development timeline Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder - continued operational progress toward a planned Phase 3 study, including constructive discussions with FDA; Phase 3 design, development, and collaboration strategy updates
11/14/24 4:01:00 PM ET
$DARE
Biotechnology: Pharmaceutical Preparations
Health Care
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Thursday, November 14, 2024, and prior to the conference call and webcast. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 6400145. The live webcast can be accessed under
11/7/24 8:00:00 AM ET
$DARE
Biotechnology: Pharmaceutical Preparations
Health Care
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today reporte
8/12/24 4:01:00 PM ET
$DARE
Biotechnology: Pharmaceutical Preparations
Health Care

Daré Bioscience Regains Compliance With Nasdaq Minimum Bid Price Rule

Chat with this insight

Recent Analyst Ratings for $DARE

$DARE FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

$DARE SEC Filings

SEC Form S-1 filed by Dare Bioscience Inc.

Dare Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Dare Bioscience Inc.

$DARE Press Releases

Fastest customizable press release news feed in the world

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

$DARE Financials

Live finance-specific insights

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

$DARE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$DARE Large Ownership Changes

This live feed shows all institutional transactions in real time.

$DARE Market Insights

Live Market Insights

$DARE Leadership Updates

Live Leadership Updates

$DARE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form 4 filed by Steele Robin Joan

SEC Form 4 filed by Kelley Susan L.

SEC Form 4 filed by Rastetter William H

SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

SEC Form SC 13G/A filed